Literature DB >> 20053567

Site-specific labeling of 'second generation' annexin V with 99mTc(CO)3 for improved imaging of apoptosis in vivo.

Marijke De Saint-Hubert1, Felix M Mottaghy, Kathleen Vunckx, Johan Nuyts, Humphrey Fonge, Kristof Prinsen, Sigrid Stroobants, Luc Mortelmans, Niko Deckers, Leo Hofstra, Chris P M Reutelingsperger, Alfons Verbruggen, Dirk Rattat.   

Abstract

In this study 'second generation' AnxV was specifically labeled with (99m)Tc in three different ways outside the binding region of the protein to obtain an improved target-to-background activity ratio. The compounds were tested in vitro and in vivo in normal mice and in a model of hepatic apoptosis (anti-Fas mAb). The apoptosis binding was most prominent for the HIS-tagged 'second generation' AnxV labeled with (99m)Tc(CO)(3) in comparison to (99m)Tc-HYNIC-cys-AnxV and (99m)Tc(CO)(3)-DTPA-cys-AnxV. Copyright (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20053567     DOI: 10.1016/j.bmc.2009.12.021

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  12 in total

1.  A dual-labeled Annexin A5 is not suited for SPECT imaging of brain cell death in experimental murine stroke.

Authors:  Marietta Zille; Denise Harhausen; Marijke De Saint-Hubert; Roger Michel; Chris P Reutelingsperger; Ulrich Dirnagl; Andreas Wunder
Journal:  J Cereb Blood Flow Metab       Date:  2014-07-02       Impact factor: 6.200

2.  Synthesis and preliminary evaluation of radiolabeled bis(zinc(II)-dipicolylamine) coordination complexes as cell death imaging agents.

Authors:  Leonie Wyffels; Brian D Gray; Christy Barber; Stephen K Moore; James M Woolfenden; Koon Y Pak; Zhonglin Liu
Journal:  Bioorg Med Chem       Date:  2011-04-28       Impact factor: 3.641

3.  Longitudinal PET imaging of doxorubicin-induced cell death with 18F-Annexin V.

Authors:  Shuo Hu; Dale O Kiesewetter; Lei Zhu; Ning Guo; Haokao Gao; Gang Liu; Naoki Hida; Lixin Lang; Gang Niu; Xiaoyuan Chen
Journal:  Mol Imaging Biol       Date:  2012-12       Impact factor: 3.488

4.  Preclinical imaging of therapy response using metabolic and apoptosis molecular imaging.

Authors:  Marijke De Saint-Hubert; Huijun Wang; Ellen Devos; Kathleen Vunckx; Lin Zhou; Chris Reutelingsperger; Alfons Verbruggen; Luc Mortelmans; Yicheng Ni; Felix M Mottaghy
Journal:  Mol Imaging Biol       Date:  2011-10       Impact factor: 3.488

Review 5.  Phosphatidylserine targeting for diagnosis and treatment of human diseases.

Authors:  Kristof Schutters; Chris Reutelingsperger
Journal:  Apoptosis       Date:  2010-09       Impact factor: 4.677

6.  In vivo molecular imaging of apoptosis and necrosis in atherosclerotic plaques using microSPECT-CT and microPET-CT imaging.

Authors:  M De Saint-Hubert; M Bauwens; N Deckers; M Drummen; K Douma; P Granton; G Hendrikx; D Kusters; J Bucerius; C P M Reutelingsperger; F M Mottaghy
Journal:  Mol Imaging Biol       Date:  2014-04       Impact factor: 3.488

7.  Straightforward thiol-mediated protein labelling with DTPA: Synthesis of a highly active 111In-annexin A5-DTPA tracer.

Authors:  Harald Kratz; Akvile Haeckel; Roger Michel; Lena Schönzart; Uli Hanisch; Bernd Hamm; Eyk Schellenberger
Journal:  EJNMMI Res       Date:  2012-04-27       Impact factor: 3.138

8.  Failure of annexin-based apoptosis imaging in the assessment of antiangiogenic therapy effects.

Authors:  Wiltrud Lederle; Susanne Arns; Anne Rix; Felix Gremse; Dennis Doleschel; Jörn Schmaljohann; Felix M Mottaghy; Fabian Kiessling; Moritz Palmowski
Journal:  EJNMMI Res       Date:  2011-11-17       Impact factor: 3.138

9.  Pharmacological Treatment with Annexin A1 Reduces Atherosclerotic Plaque Burden in LDLR-/- Mice on Western Type Diet.

Authors:  Dennis H M Kusters; Martijn L Chatrou; Brecht A G Willems; Marijke De Saint-Hubert; Matthias Bauwens; Emiel van der Vorst; Stefania Bena; Erik A L Biessen; Mauro Perretti; Leon J Schurgers; Chris P M Reutelingsperger
Journal:  PLoS One       Date:  2015-06-19       Impact factor: 3.240

10.  99mTc-HYNIC-Annexin A5 in Oncology: Evaluating Efficacy of Anti-Cancer Therapies.

Authors:  Frédéric L W V J Schaper; Chris P Reutelingsperger
Journal:  Cancers (Basel)       Date:  2013-05-15       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.